RxDoctor Payments Data

Juan Cobo, MD

Internal Medicine · Chicago, ILNPI 1588745418

Payments from drug & device makers

$286in general payments, 2019–2025

Across 12 payments — averaging $23.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$132
  • Novo Nordisk$125
  • Sunovion Pharmaceuticals Inc.$17
  • AstraZeneca$12

What the payments were for

  • Food & beverage$25489%
  • Education$3211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK7$132
Novo Nordisk2$125
Sunovion Pharmaceuticals Inc.2$17
AstraZeneca1$12

How this compares

$286 in reported general payments places this provider in the 60th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$287,329
Medicare patients
504
Services billed
3,092

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide99$165,642
EliquisApixaban128$160,821
JardianceEmpagliflozin115$135,623
Synjardy XrEmpagliflozin/Metformin Hcl98$129,343
TrulicityDulaglutide50$93,498
MounjaroTirzepatide61$84,005
XareltoRivaroxaban32$53,683
Janumet XrSitagliptin Phos/Metformin Hcl31$40,246
JanuviaSitagliptin Phosphate30$40,086
LinzessLinaclotide22$33,675
Tresiba Flextouch U-200Insulin Degludec36$25,596
MyrbetriqMirabegron31$25,261
TradjentaLinagliptin14$19,512
Breo ElliptaFluticasone/Vilanterol33$15,870
Tresiba Flextouch U-100Insulin Degludec31$13,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$125$165,64299 claims
GSKBreo Ellipta, Incruse Ellipta$132$19,70144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →